Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: Survival Estimates From the EMPA-REG OUTCOME Trial

被引：31
|
作者：
Claggett, Brian [1 ]
Lachin, John M. [2 ]
Hantel, Stefan [3 ]
Fitchett, David [4 ,5 ]
Inzucchi, Silvio E. [6 ]
Woerle, Hans J. [7 ]
George, Jyothis T. [7 ]
Zinman, Bernard [5 ,8 ]
机构：
[1] Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA
[2] George Washington Univ, Biostat Ctr, Rockville, MD USA
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[4] St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
[7] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[8] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
CIRCULATION | 2018年 / 138卷 / 15期
关键词：
cardiovascular diseases; diabetes mellitus; empagliflozin;
D O I：
10.1161/CIRCULATIONAHA.118.033810
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1599 / 1601
页数：3
相关论文
共 50 条
  • [11] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
  • [12] Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
    Sharma, Abhinav
    Ofstad, Anne Pernille
    Ahmad, Tariq
    Zinman, Bernard
    Zwiener, Isabella
    Fitchett, David
    Wanner, Christoph
    George, Jyothis T.
    Hantel, Stefan
    Desai, Nihar
    Mentz, Robert J.
    JACC-HEART FAILURE, 2021, 9 (08) : 568 - 577
  • [13] Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
    Waijer, Simke W.
    Xie, Di
    Inzucchi, Silvio E.
    Zinman, Bernard
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximillian
    Inker, Lesley A.
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (18):
  • [14] Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
    Subodh Verma
    C. David Mazer
    David Fitchett
    Silvio E. Inzucchi
    Egon Pfarr
    Jyothis T. George
    Bernard Zinman
    Diabetologia, 2018, 61 : 1712 - 1723
  • [15] Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease
    Monteiro, Pedro
    Aguiar, Carlos
    Matos, Pedro
    Silva-Nunes, Jose
    Birne, Rita
    Branco, Patricia
    Calado, Joaquim
    Melo, Miguel
    Polonia, Jorge
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2019, 38 (10) : 721 - 735
  • [16] Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOMEA® randomised trial
    Verma, Subodh
    Mazer, C. David
    Fitchett, David
    Inzucchi, Silvio E.
    Pfarr, Egon
    George, Jyothis T.
    Zinman, Bernard
    DIABETOLOGIA, 2018, 61 (08) : 1712 - 1723
  • [17] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
    Wanner, Christoph
    Lachin, John M.
    Inzucchi, Silvio E.
    Fitchett, David
    Mattheus, Michaela
    George, Jyothis
    Woerle, Hans J.
    Broedl, Uli C.
    von Eynatten, Maximilian
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    CIRCULATION, 2018, 137 (02) : 119 - 129
  • [18] Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 121 : 204 - 214
  • [19] Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
    Kamstra, Rhiannon
    Durkin, Mike
    Cai, Jennifer
    Bookhart, Brahim
    Lafeuille, Marie-Helene
    Pilon, Dominic
    Tiggelaar, Sean
    Manceur, Ameur M.
    Lefebvre, Patrick
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (03) : 280 - 287
  • [20] Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME
    Boehm, Michael
    Fitchett, David
    Ofstad, Anne Pernille
    Brueckmann, Martina
    Kaspers, Stefan
    George, Jyothis T.
    Zwiener, Isabella
    Zinman, Bernard
    Wanner, Christoph
    Marx, Nikolaus
    Mancia, Giuseppe
    Anker, Stefan D.
    Mahfoud, Felix
    JOURNAL OF HYPERTENSION, 2020, 38 (09) : 1829 - 1840
12345